FLC
SLNO

Fifth Lane Capital’s Soleno Therapeutics SLNO Stock Holding History

Fifth Lane Capital’s Portfolio SLNO Stock Details SLNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-6,550
Closed -$443K – 148
2025
Q3 		$443K Buy
+6,550
New +$486K 0.44% 45

Other funds holding SLNO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Fifth Lane Capital's SLNO Position: Q4 2025 in Review

Fifth Lane Capital sold out of Soleno Therapeutics (SLNO) in Q4 2025, closing a stake of 6,550 shares — an estimated $443K sold.

Fifth Lane Capital first reported a position in SLNO in Q3 2025 and held it in 1 quarter. The position peaked at $443K in Q3 2025. 248 funds tracked by Wall St. Rank hold SLNO as of Q4 2025.

  • Fifth Lane Capital reported no remaining Soleno Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Fifth Lane Capital sold 6,550 Soleno Therapeutics shares in Q4 2025, an estimated $443K.
  • Fifth Lane Capital first reported a position in Soleno Therapeutics in Q3 2025 and held it in 1 quarter.
  • Fifth Lane Capital's Soleno Therapeutics position peaked at $443K in Q3 2025.
  • 248 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q4 2025.

Based on Fifth Lane Capital's 13F filing for Q4 2025, filed 13 Feb 2026.